EUVIMEDEUVIMED entdecken
Open Access

Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies

Natalie McCormick iD, Nitzan Burrack iD, Chio Yokose, Na Lu, Deborah J Wexler iD, Sharan K Rai, Gregory J Challener, J Antonio Aviña-Zubieta, Rozalina G McCoy iD, Ran Abuhasira iD, Hyon K Choi iD

Diabetes Care · 2026

DOI: 10.2337/dc25-1713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Natalie McCormick und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Bo…. Hauptthemen laut MEDLINE: Gout, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Gout Suppressants. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, CIHR, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2is) lower serum urate and are associated with a lower risk of recurrent gout flares. We used target trial emulation to compare rates of allopurinol initiation and use of anti-inflammatories (high-dose glucocorticoids, nonsteroidal anti-inflammatory drugs [NSAIDs], colchicine) and diuretics (prototypic serum urate-raising medication) among patients with gout using SGLT2is versus dipeptidyl peptidase 4 inhibitors (DPP-4is) (primary comparator), with glucagon-like peptide 1 receptor agonists (GLP-1RAs) as an alternative comparator. RESEARCH DESIGN AND METHODS From a general population database, we identified patients with gout and comorbid type 2 diabetes and used Cox proportional hazards and Poisson regressions with inverse probability of treatment weighting to emulate randomization to SGLT2i or DPP-4i/GLP-1RA. We also replicated the analysis in an electronic health record data set with further adjustment for serum urate and BMI. RESULTS Among 26,739 adults with gout and type 2 diabetes (mean age 66 years), 67% had polypharmacy. Allopurinol initiation was lower among SGLT2i initiators than DPP-4i, with a hazard ratio of 0.62 (95% CI 0.52–0.73). Associations were stronger among those using diuretics at baseline (P for interaction = 0.03) and persisted when comparing SGLT2i with GLP-1RA and accounting for serum urate and BMI in the secondary data set. SGLT2i was also associated with lower rates of high-dose glucocorticoid, NSAID, colchicine, and diuretic dispensing, with rate ratios of 0.78 (95% CI 0.74–0.83), 0.85 (95% CI 0.80–0.92), 0.87 (95% CI 0.83–0.92), and 0.87 (95% CI 0.85–0.89), respectively. CONCLUSIONS For patients with gout and type 2 diabetes, SGLT2is may reduce gout-related medication use, which could, in turn, reduce exposure to the harmful cardiovascular-kidney-metabolic effects of NSAIDs and glucocorticoids in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGout SuppressantsHumansFemaleMiddle AgedAgedMaleAnti-Inflammatory Agents, Non-SteroidalColchicineAllopurinolDipeptidyl-Peptidase IV InhibitorsDiureticsGlucocorticoids

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGout SuppressantsAnti-Inflammatory Agents, Non-SteroidalColchicineAllopurinolDipeptidyl-Peptidase IV InhibitorsDiureticsGlucocorticoids

Autor:innen und Institutionen

  • Rheumatology and Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.
  • The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA.
  • Department of Medicine, Harvard Medical School, Boston, MA.
  • Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel.
  • Diabetes Center, Massachusetts General Hospital, Boston, MA.

ORCID-Profile: Natalie McCormick, Nitzan Burrack, Deborah J Wexler, Rozalina G McCoy, Ran Abuhasira, Hyon K Choi

Förderung

  • NIAMS NIH HHS
  • CIHR
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Canadian Institutes of Health Research

Zitieren

APA

McCormick, N., Burrack, N., Yokose, C., Lu, N., Wexler, D. J., Rai, S. K., Challener, G. J., Aviña-Zubieta, J. A., McCoy, R. G., Abuhasira, R., & Choi, H. K. (2026). Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. Diabetes Care. https://doi.org/10.2337/dc25-1713

Vancouver

McCormick N, Burrack N, Yokose C, Lu N, Wexler DJ, Rai SK, et al. Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. Diabetes Care. 2026. doi:10.2337/dc25-1713

BibTeX
@article{McCormick2026,
  author = {McCormick, Natalie and Burrack, Nitzan and Yokose, Chio and Lu, Na and Wexler, Deborah J and Rai, Sharan K and Challener, Gregory J and Aviña-Zubieta, J Antonio and McCoy, Rozalina G and Abuhasira, Ran and Choi, Hyon K},
  title = {Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc25-1713}
}
Kostenlos starten →